Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Cerilliant
Johnson and Johnson
Express Scripts
Harvard Business School
Colorcon
Moodys
McKinsey
Argus Health

Generated: October 19, 2017

DrugPatentWatch Database Preview

Clindamycin phosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for clindamycin phosphate and what is the scope of clindamycin phosphate patent protection?

Clindamycin phosphate
is the generic ingredient in seventeen branded drugs marketed by Alvogen Inc, Watson Labs, Pharmacia And Upjohn, Mylan Pharms Inc, Wockhardt, Loch, West-ward Pharms Int, Bristol Myers Squibb, Sagent Pharms, Novast Labs Ltd, G And W Labs Inc, Marsam Pharms Llc, Akorn, Solopak, Abbvie, Igi Labs Inc, Paddock Llc, Vintage Pharms, Abraxis Pharm, Perrigo Co, Fougera Pharms, Teva Parenteral, Boca Pharma Llc, Teligent Pharma Inc, Fresenius Kabi Usa, Mylan Labs Ltd, Akorn Inc, Baxter Hlthcare, Perrigo New York, Fougera Pharms Inc, Bedford, Precision Dermat, Baxter Hlthcare Corp, Taro Pharm Inds, Perrigo Uk Finco, Sandoz Inc, Perrigo Pharma Intl, Medicis, Aqua Pharms Llc, and Actavis Mid Atlantic, and is included in sixty-nine NDAs. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Clindamycin phosphate has one hundred and twenty-three patent family members in thirty-six countries and nine supplementary protection certificates in eight countries.

There are fifty-three drug master file entries for clindamycin phosphate. Thirty-three suppliers are listed for this compound.

Summary for Generic Name: clindamycin phosphate

US Patents:6
Tradenames:17
Applicants:40
NDAs:69
Drug Master File Entries: see list53
Suppliers / Packagers: see list33
Bulk Api Vendors: see list55
Clinical Trials: see list909
Patent Applications: see list1,697
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:clindamycin phosphate at DailyMed

Pharmacology for Ingredient: clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Solopak
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION062819-001Mar 15, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CLEOCIN
clindamycin phosphate
SWAB;TOPICAL050537-002Feb 22, 1994ATRXYesNo► Subscribe► Subscribe► Subscribe
Akorn
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
SWAB;TOPICAL065513-001Jun 17, 2010ATRXNoNo► Subscribe► Subscribe► Subscribe
Vintage Pharms
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
SOLUTION;TOPICAL062930-001Jun 28, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CLEOCIN T
clindamycin phosphate
LOTION;TOPICAL050600-001May 31, 1989ABRXYesYes► Subscribe► Subscribe► Subscribe
Akorn Inc
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION203048-002Apr 4, 2013APRXNoNo► Subscribe► Subscribe► Subscribe
Loch
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION062905-001May 9, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Alvogen Inc
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION062943-001Sep 29, 1988APRXNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare Corp
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
clindamycin phosphate
SOLUTION;IV (INFUSION)208083-002Apr 20, 2017RXYesYes► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
CLINDAMYCIN PHOSPHATE
clindamycin phosphate
INJECTABLE;INJECTION062953-001Apr 21, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl
CLINDESSE
clindamycin phosphate
CREAM;VAGINAL050793-001Nov 30, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: clindamycin phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,488Pharmaceutical foam► Subscribe
6,416,778 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,652,874 Pharmaceutical preparations and methods for their regional administration► Subscribe
9,486,394Pharmaceutical foam► Subscribe
8,586,008Pharmaceutical foam► Subscribe
6,517,847 Topical gel delivery system► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: clindamycin phosphate

Country Document Number Estimated Expiration
Poland213237► Subscribe
Spain2326955► Subscribe
Portugal2052714► Subscribe
South Korea20030057526► Subscribe
Spain2260828► Subscribe
Brazil0113247► Subscribe
France2837389► Subscribe
Germany69834025► Subscribe
Germany60138549► Subscribe
Japan2003286193► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLINDAMYCIN PHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
4Finland► Subscribe
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
AstraZeneca
UBS
Baxter
Cipla
Fish and Richardson
Dow
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot